Free Trial

Organon & Co. (OGN) Stock Price, News & Analysis

-0.36 (-1.69%)
(As of 05/24/2024 08:50 PM ET)
Today's Range
50-Day Range
52-Week Range
1.04 million shs
Average Volume
2.60 million shs
Market Capitalization
$5.40 billion
P/E Ratio
Dividend Yield
Price Target

Organon & Co. MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
7.7% Upside
$22.60 Price Target
Short Interest
4.71% of Float Sold Short
Dividend Strength
Based on Four Factors
Upright™ Environmental Score
News Sentiment
0.95mentions of Organon & Co. in the last 14 days
Based on 8 Articles This Week
Insider Trading
Proj. Earnings Growth
From $4.30 to $4.36 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.23 out of 5 stars

Medical Sector

139th out of 922 stocks

Pharmaceutical Preparations Industry

53rd out of 422 stocks

OGN stock logo

About Organon & Co. Stock (NYSE:OGN)

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.

OGN Stock Price History

OGN Stock News Headlines

CUPE 37 Members Reject City of Calgary Wage Package
Four Reasons Why Organon Stock Is A Good Buy
Organon declares $0.28 dividend
Piper Sandler Reaffirms Their Buy Rating on Organon (OGN)
Organon & Co. (OGN)
OGN Quantitative Stock Analysis
See More Headlines
Receive OGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organon & Co. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 3/14 Dividend
Dividend Payable
Last Earnings
Ex-Dividend for 6/13 Dividend
Dividend Payable
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$1.02 billion
Pretax Margin


Sales & Book Value

Annual Sales
$6.35 billion
Cash Flow
$5.02 per share
Book Value
$0.19 per share


Free Float
Market Cap
$5.40 billion
Not Optionable
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Kevin Ali (Age 64)
    CEO & Director
    Comp: $3.96M
  • Mr. Matthew M. Walsh (Age 57)
    Executive VP & CFO
    Comp: $1.84M
  • Ms. Susanne Gabriele Fiedler (Age 55)
    Executive VP & Chief Commercial Officer
    Comp: $1.44M
  • Mr. Joseph T. Morrissey Jr. (Age 58)
    Executive VP and Head of Manufacturing & Supply
    Comp: $1.54M
  • Ms. Rachel A. Stahler (Age 48)
    Executive VP & Chief Information Officer
  • Ms. Jennifer Halchak
    Head of Investor Relations
  • Mr. Kirke Weaver (Age 50)
    Executive VP, General Counsel & Corporate Secretary
  • Ms. Susan O'Neal
    Chief Ethics & Compliance Officer
  • Ms. Rebecca Lowell Edwards
    Chief Communications Officer
  • Mr. Daniel Karp (Age 46)
    Chief Business Development Officer

OGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Organon & Co. stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organon & Co. in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" OGN shares.
View OGN analyst ratings
or view top-rated stocks.

What is Organon & Co.'s stock price target for 2024?

4 brokers have issued twelve-month price targets for Organon & Co.'s stock. Their OGN share price targets range from $19.00 to $28.00. On average, they expect the company's share price to reach $22.60 in the next year. This suggests a possible upside of 7.7% from the stock's current price.
View analysts price targets for OGN
or view top-rated stocks among Wall Street analysts.

How have OGN shares performed in 2024?

Organon & Co.'s stock was trading at $14.42 at the start of the year. Since then, OGN stock has increased by 45.6% and is now trading at $20.99.
View the best growth stocks for 2024 here

When is Organon & Co.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our OGN earnings forecast

How were Organon & Co.'s earnings last quarter?

Organon & Co. (NYSE:OGN) released its quarterly earnings data on Thursday, May, 2nd. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.83 by $0.31. The firm had revenue of $1.62 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 16.50% and a negative trailing twelve-month return on equity of 360.57%.

How often does Organon & Co. pay dividends? What is the dividend yield for Organon & Co.?

Organon & Co. announced a quarterly dividend on Thursday, May 2nd. Shareholders of record on Monday, May 13th will be paid a dividend of $0.28 per share on Thursday, June 13th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 5.34%. The ex-dividend date is Friday, May 10th.
Read our dividend analysis for OGN

Is Organon & Co. a good dividend stock?

Organon & Co. (NYSE:OGN) pays an annual dividend of $1.12 per share and currently has a dividend yield of 5.10%. OGN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 27.38%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, OGN will have a dividend payout ratio of 25.69% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for OGN.

What guidance has Organon & Co. issued on next quarter's earnings?

Organon & Co. issued an update on its FY 2024 earnings guidance on Friday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $6.2 billion-$6.5 billion, compared to the consensus revenue estimate of $6.4 billion.

Who are Organon & Co.'s major shareholders?

Organon & Co.'s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.97%), LSV Asset Management (1.75%), Nordea Investment Management AB (1.54%), Principal Financial Group Inc. (1.11%), Private Management Group Inc. (0.90%) and Russell Investments Group Ltd. (0.64%). Insiders that own company stock include Kirke Weaver and Ma Fatima Francisco.
View institutional ownership trends

How do I buy shares of Organon & Co.?

Shares of OGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:OGN) was last updated on 5/27/2024 by Staff

From Our Partners